The Conversation (0)
Corbus Pharmaceuticals Holdings announced it started their Phase 3 study for the efficacy and safety of anabasum in the treatment of systemic sclerosis.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announced it started their Phase 3 study for the efficacy and safety of anabasum in the treatment of systemic sclerosis.
As quoted in the press release:
Systemic sclerosis is a serious autoimmune disease affecting approximately 90,000 people in the United States and Europe and is associated with significant morbidity and up to 60% 10-year mortality. There are currently no drugs specifically approved by the U.S. Food and Drug Administration (“FDA”) for treatment of systemic sclerosis.
The international multicenter Phase 3 RESOLVE-1 study is a double-blind, randomized, placebo-controlled study assessing the efficacy and safety of anabasum for the treatment of systemic sclerosis. The study will enroll approximately 354 subjects at 70 sites in North America, Europe, Israel, Japan, South Korea, and Australia. The planned duration of treatment with study drug is 52 weeks. Subjects will be randomized 1:1:1 to receive anabasum 5 mg twice per day, anabasum 20 mg twice per day, or placebo twice per day.
Click here to read the full press release.
Source: www.marketwired.com
